Clinical trial
Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas
NCT00352521 is registered in ClinicalTrials.gov with Duke University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas
- Lead sponsor
- Duke University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- July 31, 2009
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
brain and central nervous system tumors